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For protection against intracellular bacteria such as Mycobacterium tuberculosis and Listeria monocytogenes, the cellular arm of
adaptive immunity is necessary. A variety of immunization methods have been evaluated and are reported to induce speciﬁc CD8+
T cells against intracellular bacterial infection. Modiﬁed BCG vaccines have been examined to enhance CD8+ T-cell responses.
Naked DNA vaccination is a promising strategy to induce CD8+ T cells. In addition to this strategy, live attenuated intracellular
bacteria such as Shigella, Salmonella,a n dListeria have been utilized as carriers of DNA vaccines in animal models. Vaccination
with dendritic cells pulsed with antigenic peptides or the cells introduced antigen genes by virus vectors such as retroviruses is
also a powerful strategy. Furthermore, vaccination with recombinant lentivirus has been attempted to induce speciﬁc CD8+ T
cells. Combinations of these strategies (prime-boost immunization) have been studied for the eﬃcient induction of intracellular
bacteria-speciﬁc CD8+ Tc e l l s .
1.Introduction
The types of eﬀective immune responses against infec-
tious diseases depend on the location of the pathogens
responsible. Generally extracellular pathogens are vulnerable
to antibody-mediated eﬀector mechanisms. On the other
hand, protection against intracellular pathogens depends on
the induction of speciﬁc cell-mediated immunity [1, 2].
Induction of eﬀective resistance to infection depends on
vaccines with the capacity of eliciting certain eﬀectors.
In this review, we focused on strategies for the induction
of CD8+ T cells against intracellular bacterial infections.
CD8+ cytotoxic T-lymphocytes (CTL) are the main eﬀectors
against bacteria, such as Rickettsia or Listeria monocytogenes,
located in the cytoplasm of host cells, while CD4+ type 1
helper T (Th1) cells play a pivotal role in the protection
against infections caused by intracellular bacteria, such as
Mycobacterium or Salmonella, located in vacuolar compart-
ments. Many reports have indicated that in addition to Th1
cells, CD8+ CTL are also important for protection against
these bacteria. After CD8+ CTL are antigen-presented, they
directly kill the infected cells with an oriented release of
granules like perforin and granzymes, as well as by granule-
independent mechanisms (reviewed in [3]). Therefore, the
induction of the bacteria-speciﬁc CD8+ T cells at an appro-
priate timing and magnitude is a key factor for protection
against infections. Attenuated vaccines have been used for
the induction of cellular immunity including that of CD8+
T cells. However, a variety of immunization methods have
been recently reported to eﬀectively induce speciﬁc CD8+ T
cells. We reviewed methods to induce CD8+ T cells speciﬁc
for intracellular pathogenic bacteria with emphasis on our
eﬀorts to induce CD8+ T cells speciﬁc for Mycobacterium
tuberculosis and L. monocytogenes.
2.IntracellularBacteria
Several bacteria have evolved in their mechanisms that allow
them to survive in the host cells. These bacteria are consid-
ered intracellular based on their localization within the host
cells, and are further categorized based on several criteria:
bacteriasuchasChlamydiaandRickettsiathatcannotsurvive2 Journal of Biomedicine and Biotechnology
Table 1: Intracellular bacteria.
Intracytosolicbacteria
Listeria monocytogenes∗ Shigella ﬂexneri∗
Rickettsia prowaseki
Intravascular bacteria
Mycobacterium spp. (M. tuberculosis, M. bovis, M. avium)
Nocardia asteroides
Legionella pneumophila, Chlamydia trachomatis
Intralysosomalbacteria
Salmonella enterica Typhimurium∗, Salmonella enterica Typhi
Yersinia enterocolitica∗, Coxiella burnetii
Asterisks indicate bacteria utilized as carrier for DNA vaccine.
outside host cells are called obligate intracellular bacteria.
On the other hand, facultative intracellular bacteria such as
Salmonella, Mycobacteria, Shigella,a n dListeria can survive
outside of host cells.
Intracellular bacteria are also divided into three diﬀerent
groups depending on their intracellular niche (Table 1,
reviewed in [4]) as follows: (1) cytoplasmic bacteria, which
exit the phagosome and reside in the host cell cytoplasm: (2)
intravascular bacteria, which persist in nonacidic vacuoles
that have little interaction with the endosomal system of
the host cells: and (3) intralysosomal bacteria, which persist
in acidic, hydrolytic compartments that interact with the
endosomal network of host cells.
(1) Cytoplasmic Bacteria. L. monocytogenes is a typical cyto-
plasmic, gram-positive, facultative intracellular bacterium.
The L. monocytogenes infection system in mice has been
studied and regarded as an excellent model system for
intracellular bacterial infections [2, 5]. This bacterium has
been known to induce major histocompatibility complex
(MHC) class I-restricted CD8+ T-cell responses in addition
to MHC class II-restricted CD4+ T-cell responses since it
is capable of escaping from the phagocytic vesicles into the
cytoplasm of the host cells with the help of listeriolysin O
(LLO; Hly), thereby introducing the bacterial proteins into
theMHCclassIantigenprocessingpathway.BothCD8+ CTL
and CD4+ Th1 have been shown to be ampliﬁed in listerial
infections and to play a critical role in protective immunity.
(2)IntravascularBacteria. BacteriasuchasMycobacteria and
Nocardia have been shown to block the normal matura-
tion steps of phagosomes of host cells. In other words,
these bacteria inhibit the phagosome-lysosome fusion after
being phagocytosed. Vacuoles containing Mycobacteria do
not acidify below pH 6.2 to 6.5 and exhibit paucity of
the vacuolar proton ATPase, which is responsible for the
acidiﬁcation of endosomal and lysosomal compartments.
For protection against M. tuberculosis infection, both CD4+
T cells and CD8+ T cells have been shown to be critical [1, 2].
(3) Intralysosomal Bacteria. Salmonella has been reported
to belong to the intralysosomal bacteria. More than 2000
serotypesofSalmonellahavebeendescribed.DNAhomology
analysis revealed that the genus consists of two species: S.
enterica and S. bongori. S. enterica is further subdivided into
six subgroups both phenotypically and genetically. Bacteria
that belong to S. enterica are often brieﬂy designated as S.
Typhimurium and S. Enteritidis based on their serotypes
for convenience sake. Salmonella penetrates through M cells
into the Peyer’s patches where they are phagocytosed by the
underlying macrophages. The precise nature of Salmonella-
containing vacuoles is controversial and is dependent on
investigatorsandthetypesofthecellsinfectedbySalmonella,
but,thevacuolesinhabitedbySalmonellahavecharacteristics
consistent with those that are late endosomal or lysosomal
in nature. Salmonella vacuoles in macrophages are subject
to be acidiﬁed by the fusion with lysosomes. Although the
acidiﬁcation of these vacuoles is partially reduced in those
containing liveSalmonella, thepHofthevacuolescontaining
live bacteria is still relatively acidic. Yersinia also belongs to
thiscategory.AfterpassingthroughMcells,theyareengulfed
by macrophages and carried to the mesenteric lymph nodes
where replication occurs.
CD8+ T cells have been considered to be critical for
protection against these intracellular bacterial infections,
especially, intracytosolic and intravascular bacterial infec-
tions. Intracellular bacteria themselves have been used as
attenuated bacterial vaccines and also as carriers of DNA
vaccines.
3. Antigen ProcessingandPresentation
Requiredfor CTL Induction
Both CTL and helper T cells have the same T-cell receptor
molecules on their surfaces, apart from CD8 and CD4
molecules on their surfaces, respectively. Antigens (antigenic
peptides) in association with MHC class I molecules on the
surface of antigen-presenting cells (APC) are presented to
CD8+ CTL. Furthermore, antigens in association with MHC
class II molecules are presented to CD4+ Th cells. Therefore,
the eﬃcient induction of CTL and Th cells requires eﬃcient
presentation of antigenic molecules via MHC class I and II
antigen processing and presentation pathways, respectively
(reviewed in [6]).
MHC class I molecules have been shown to be expressed
in almost all somatic cells except for neurons and germ
c e l l s .I no r d e rt op r i m eC D 8 + CTL, antigenic peptides must
be presented on MHC class I molecules on the surface of
professional APC that possess special accessory molecules.
In general, proteins located in the cytoplasm of APC
(endogenous antigens) are processed with the proteasome
complex and selected peptides go into the endoplasmic
reticulum (ER) through transporters associated with antigen
processing (TAP) molecules. Antigenic peptides of 8 to 10
amino acid residues bind to the groove of MHC class I
molecules in the ER after which they travel to the cell surface
a n da r ep r e s e n t e dt oC D 8 + Tc e l l s( r e v i e w e di n[ 7]).
A new type of antigen presentation pathway to induce
CD8+ T cells against intravesicular bacteria such as M.
tuberculosis has been proposed [8, 9]. Intracellular bacteria
induce apoptosis in infected macrophages after they areJournal of Biomedicine and Biotechnology 3
phagocytosed. The formed apoptotic vesicles are captured
by dendritic cells (DC) and induce CD8+ T cells. This cross-
priming pathway explains how intravesicular bacteria induce
CD8+ T cells.
4.AttenuatedBacteriaVaccination
Mycobacterium bovis bacillus Calmette-Gu´ erin (BCG) is the
only approved vaccine to date against tuberculosis (TB) and
the most widely distributed attenuated bacterial vaccine [10,
11]. Despite BCG is among the most widely used vaccines
throughout the world, TB still poses a serious global health
threat. Whereas BCG is believed to protect newborn and
youngchildrenagainstearlymanifestationsofTB,itseﬃcacy
againstpulmonaryTBinadultsisstillasubjectofdebate[12]
and was reported to wane with time since vaccination [13].
Moreover, the viable nature of BCG makes it partly unsafe
in case of immunocompromised individuals. This highlights
theneedtodevelopamoreeﬀective,safe,andreliablevaccine
against TB [14]. One of weak points of BCG vaccination
is that the vaccination cannot induce strong CD8+ T-cell
responses. In contrast to M. tuberculosis,g r o w t ho fB C G
is not aﬀected in mice lacking β2-microglobulin [15, 16].
The weak CD8+ T-cell responses by BCG vaccination may
be caused by weak invasiveness of BCG compared with M.
tuberculosis. In order to enhance CD8+ T-cell responses by
BCG, Kaufmann’s group reported recombinant BCG strain
harboring listeriolysin O (LLO; LLO) derived from L. mono-
cytogenes [17]. LLO is a pore-forming sulfhydryl-activated
cytolysin and is essential for the release of L. monocytogenes
from phagosomal vacuoles into the cytoplasm of host cells.
Although recombinanthly+ BCG strain expressing LLO did
not egress into the cytoplasmic compartment of host cells,
it improved MHC class I presentation of cophagocytosed
ovalbumin as compared with wild-type BCG strain. Further,
they developed urease C-deﬁcient hly+ BCG [18]. Urease
C deﬁciency inhibits to increase an intraphagosomal pH
and facilitates LLO activity. They found that LLO promotes
antigen translocation into the cytoplasm and enhance not
only CD8+ T-cell responses via cross-priming mechanisms,
but also the apoptosis of infected macrophages. One of
other well-studied recombinant BCG is BCG overexpressing
antigen 85B (Ag85B) gene (rBCG30) [19]. Ag85B is one of
the major secreted proteins in Mycobacteria and the over-
expressing BCG elicits more eﬀective protective immunity
against M. tuberculosis challenge.
In addition to recombinant BCG, a variety of live
attenuatedM.tuberculosisstrainshavebeenreported.Several
strategiesarebeingpursuedtodeveloptheattenuatedstrains,
which include auxotrophs (strains that are able to grow only
insupplementationofparticularnutrients)andmutantsthat
have deletions in virulence genes such as RD1 (region of
deletion-1) genes.
Recombinant attenuated Salmonella strains have also
been examined for vaccines against M. tuberculosis.W a n g
et al. [20] reported that orogastrical immunization of
BALB/c mine by a live attenuated Salmonella Typhimurium
strain harboring the M. tuberculosis ESAT6 (early secreted
antigenic target 6-kDa protein)-Ag85B fusion gene or
DNA vaccine
Ampicillin
resistance
Target gene
Intron
CMV I.E.
Enhancer/promoter
SV40 late
polyA
(a) Gene gun system
DNA vaccine
Ampicillin
resistance
Target gene
Intron
CMV I.E.
Enhancer/promoter
SV40 late
polyA
Attenuated bacteria
(b) Attenuated bacteria carrier system
Figure 1: DNA vaccination system. (a) Naked DNA vac-
cination. Eukaryotic expression plasmids that have a strong
enhancer/promoter such as cytomegalovirus immediate-early pro-
moter/enhancer are used as DNA vaccines. Naked DNA vaccination
carriedoutbyneedleinjection(intramuscular,subcutaneous),gene
gun bombardment, or topical application to skin. (b) Live attenu-
ated bacteria carrier DNA vaccination. Live attenuated intracellular
bacteria, such as Listeria, Shigella,o rSalmonella,areusedascarriers
of DNA vaccines. They were given orally or parenterally (needle
injection).
combination of this vaccine with BCG vaccine induced
strong Ag85B-speciﬁc mucosal humoral and cellular
immune responses including eﬀector CD8+ T-cell responses
and exerted high protective eﬃcacy in mice against M.
tuberculosis challenge. Cross-priming mechanisms may
occur for the CD8+ T-cell responses by these recombinant
Salmonella vaccines.
5. DNA Vaccination
DNA vaccination is a method by which target antigen
genes are directly introduced into host cells. The vaccination
strategy is categorized into two groups (Figure 1). One is
the so-called naked DNA vaccination. Eukaryotic expression
plasmids encoding target antigen genes are used for this
strategy.ImmunizationmethodsforthenakedDNAvaccines
are intramuscular injections, gene gun bombardment of
DNA-coated gold particles into the epidermis, intrader-
mal DNA immunization [21], and topical application of
D N Av a c c i n e s[ 22]. The other is carrier-mediated DNA
vaccination. Liposomes, microparticle encapsulation, and
attenuated bacteria have been examined as carriers of DNA
(reviewed in [23, 24]). Here we brieﬂy review naked DNA
vaccination and attenuated bacteria carrier DNA vaccination
for the induction of CD8+ T cells speciﬁc for intracellular
bacterial infections.4 Journal of Biomedicine and Biotechnology
5.1. Naked DNA Vaccination. Genetic immunization with
naked DNA has been shown to eﬃciently induce cellular
as well as humoral immune responses. The reason why
this method produces an eﬃcient induction of immune
responses is due to the fact that it involves eﬃcient antigen
presentation through DC [25, 26]. It is of particular interest
that the amount of DNA required by gene gun DNA immu-
nization is 100 to 1000 times less DNA than that by muscle
DNA inoculation to generate equivalent antibody responses
[27]. Muscle DNA immunization raises predominant Th1
responses, while gene gun DNA immunization is apt to
producetype2helperT(Th2)responses[28].Thisdiﬀerence
is considered to be mainly due to the diﬀerence in (1) the
amount of antigen produced from the plasmids and (2) the
amount of CpG motif present in plasmid DNA vaccines.
In addition, gene gun DNA immunization has brought
about highly reproducible and reliable results in antibody
production and the induction of speciﬁc CD8+ CTL and
interferon-γ (IFN-γ) production from immune splenocytes
[29].
Codon usage is a problem for the eﬀective induction
of speciﬁc immune responses by DNA vaccination against
pathogenic bacteria. We constructed a plasmid DNA vac-
cine harboring a wild-type DNA sequence of a dominant
CTL epitope of L. monocytogenes derived from LLO 91–99
(GYKDGNEYI). We then attempted to immunize mice with
the DNA vaccine by intramuscular injection. However, this
vaccine could not clearly induce LLO 91–99-speciﬁc CTL
in BALB/c mice [30]. A reason for the induction failure
may be the diﬀerence in codon usage between mammalian
cells and L. monocytogenes.T h eL. monocytogenes genome
is highly A+T-rich. In contrast, the mammalian genome
is G+C-rich. This diﬀerence may aﬀect the eﬃciency of
L. monocytogenes gene expression in mammalian cells. To
address this diﬀerence, we examined a DNA vaccine using
the LLO 91–99 gene whose codons were optimized to
those of the mammalian cells. The codon-optimized DNA
vaccine gave an excellent speciﬁc CD8+ CTL induction
by intramuscular immunization [30]. We further evaluated
the codon optimization eﬀect on CTL induction using the
DNA vaccine [31]. In this previously performed study,
using mammalian culture cells, we analyzed the translation
eﬃciency of several genes composed of diﬀerent levels of
optimization to mammalian cells but encoding an identical
CTL epitope derived from L. monocytogenes (LLO 91–99)
and showed that the codon optimization level of the genes
is not precisely proportional to, but correlates well with
the translation eﬃciency in mammalian cells. These results
also correlated well with the induction level of speciﬁc CTL
response in vivo [31].
Several studies have been performed on the eﬃcient
induction of CTL of a particular speciﬁcity. We have
demonstrated that the minigene DNA vaccine encoding only
a dominant CTL epitope of L. monocytogenes (LLO 91–
99) was eﬀective for inducing CTL in vivo by gene gun
DNA immunization [30]. This result suggests that the DNA
vaccineplasmidsaredirectlytakenupbyAPC,whichpresent
target peptides to T cells by DNA immunization. Injection of
a single CTL epitope minigene DNA generates a single CTL
epitope peptide, which is supposed to enter the ER with the
help of TAP molecules. However, Cho et al. [32]s u g g e s t e d
thatcross-primingisapredominantmechanismforinducing
CD8+ T cell responses in gene gun DNA immunization.
Some CTL epitopes have been modiﬁed to have greater
immunogenic capacity by substituting several amino acid
residues (epitope enhancement) [33].
As one particular approach for the eﬃcient induction
of a CD8+ T-cell subset, Wolkers et al. [34] showed that
the carboxy-terminal fusion of a CTL epitope to a carrier
proteinofforeignorigineﬃcientlyinducedCD8+ CTL.They
constructed DNA vaccines by encoding a carboxy-terminal
fusion of CTL epitopes (NP 366–374 derived from inﬂuenza
virus or E7 49–57 derived from human papilloma virus) into
green ﬂuorescent protein (GFP) and showed that the DNA
vaccinesinducedamuchlargerclonalsizeofantigen-speciﬁc
CD8+ CTL by intramuscular immunization compared to the
clonal size induced by these epitope minigene DNA vaccines.
The purpose of the GFP fusion strategy was to provide
CD4+ T-cellhelpbyrecognizingCD4+ T-cellepitopesinGFP
protein. Maecker et al. [35] also showed that CTL induction
by both intramuscular and intradermal DNA administration
is dependent upon the generation of CD4+ T-cell help via
the class II MHC-dependent pathway. Our results showed
that CTL minigene DNA vaccination by gene gun DNA
immunization induced speciﬁc CTL without any CD4+ T-
cell help [36]. We speculate that the method of naked
DNA immunization (needle injection or gene gun injection)
determines requirement for CD4+ T-cell help.
Several studies have attempted to produce multimerized
CTL epitope DNA vaccines (polyepitope DNA vaccines).
This vaccine was ﬁrst evaluated by Whitton et al. [37].
They generated a recombinant vaccinia virus system for
the expression of CTL-epitope minigenes tandemly fused
in a “string-of-beads” manner and showed that this vac-
cine can induce CD8+ CTL speciﬁc for each diﬀerent
epitope and protect vaccinated animals against infections.
Subsequently, Thomson et al. [38]c o n s t r u c t e daD N A
vaccine plasmid containing 10 contiguous minimal CTL
epitopes, which were restricted by ﬁve MHC alleles derived
from ﬁve viruses (inﬂuenza virus, adenovirus, murine
cytomegalovirus, Sendai virus, and lymphocytic chori-
omeningitis virus), a murine malaria parasite (Plasmodium
berghei), and a tumor model antigen (ovalbumin). They
administered in mice with the plasmid by intramuscular
injection or gene gun-mediated intradermal injection and
showed that the DNA vaccination successfully induced each
epitope-speciﬁc CTL activity. Results of our single CTL-
epitope DNA vaccine showed that a single dominant CTL
epitope is suﬃcient for the induction of protective immunity
[39], suggesting that selecting the most eﬀective CTL epitope
for each pathogen is critical for the eﬃcacy of DNA vaccines.
Although some reports have suggested that the ﬂanking
sequences of a CTL epitope are important for the precise
processingoftheCTLepitopeinvivoandthatsomeCTLepi-
topes will interfere with other epitope function (Del Val et al.
[40]), a majority of reports have shown that immunization
with multimerized CTL epitope DNA without any spacer
successfully induces CTL speciﬁc for each CTL epitope.Journal of Biomedicine and Biotechnology 5
However, some reports (e.g., Velders et al. [41])suggestedthe
importance of deﬁned ﬂanking sequences around epitopes
and the addition of ubiquitin. Ishioka et al. [42]e v a l u a t e d
minigene DNA vaccines encoding multiple HLA-restricted
CTL epitopes employing HLA class I-transgenic mice. Such
studies are useful as pilot experiments to evaluate DNA
vaccines before attempting human studies.
We haveused this naked DNA vaccination foridentifying
immunodominant CD8+ T-cell epitopes of M. tuberculosis
antigens [43–45]. We have used gene gun DNA immu-
nization because it is highly reproducible and eﬃciently
induces CD8+ T cells [28]. After immunization, immune
spleen cells were examined for their responses to overlap-
ping peptides covering full-length proteins by measuring
IFN-γ levels by enzyme-linked immunosorbent assay or by
counting the numbers of IFN-γ-secreting cells by enzyme-
linked immunospot assay. We combined these methods with
computer algorithms, such as BIMAS [46]a n dS Y F P E I T H I
[47], to predict T-cell epitopes. These programs were helpful
for reducing the amino acid region of the bona ﬁde T-
cell epitope. However, the algorithms are still not perfect
for accurate identiﬁcation of T-cell epitopes at this time.
A peptide that shows the highest score in these algorithms
is not necessarily the best T-cell epitope. Experimental
validation is deﬁnitely necessary to determine actual CD8+
T-cell epitopes.
5.2. Live Attenuated Bacteria Carrier DNA Vaccination. Live
attenuated bacteria, particularly intracellular bacteria, have
been examined as carriers of DNA vaccines [48]. Advantages
of these vaccination systems include (1) possible mucosal
route of immunization, (2) propensity to infect APC, (3)
relative ease of genetic manipulation, (4) adjuvant eﬀects of
carrier bacteria, (5) possible ampliﬁcation of DNA vaccine
plasmidsinvivo,and(6)simplicityofhandlingandstocking.
Salmonella, Listeria,a n dShigella have been mainly examined
for this purpose.
5.2.1. Shigella as a Carrier of DNA Vaccines. The ﬁrst
reported DNA vaccine-carrying bacterium was Shigella.
Sizemore et al. [49, 50] showed that the strain S. ﬂexneri 2a
15D harboring a plasmid expressing the lacZ reporter gene,
which is controlled by an in vivo-induced promoter, elicited
modest antibody and cellular immune responses against the
reporter protein. The Shigella strain 15D (a derivative of
the wild-type S. ﬂexneri 2a strain 2457T) harbors a deletion
mutation in the asd gene encoding aspartate β-semialdehyde
dehydrogenase,anessentialenzymerequiredforsynthesizing
the bacterial cell wall constituent diaminopimelic acid
(DAP). The strain 15D retains invasiveness for mammalian
cells but cannot survive in the absence of DAP supplemen-
tation in vivo. The use of an invasive yet nonreplicating
attenuated vector such as 15D may be suitable for delivering
plasmid DNA vaccines to mucosal lymphoid tissues. This
study was supported by experiments in mice intranasally
immunized with the strain 15D expressing measles virus
envelope protein or nucleoprotein (NP) by Fennelly et al.
[51]. They showed that mice vaccinated with the strain
15D harboring plasmid vectors encoding diﬀerent measles
virus antigens induced a vigorous antigen-speciﬁc response
against measles virus. They observed the production of
measles virus protein-speciﬁc CD8+ T cells and IFN-γ
responses, as well as modest production of speciﬁc serum
antibodies.
5.2.2. Salmonella as a Carrier of DNA Vaccines. An attenu-
ated Salmonella strain widely used is the S. Typhimurium
aroA strain [52], which interferes with the biosynthesis of
aromatic amino acids. Darji et al. [53] reported that orally
administered attenuated S. Typhimurium aroA carrying
plasmids containing the coding sequence of β-galactosidase
(β-gal)of Escherichiacoli,ortruncatedformsofActAorLLO
of L. monocytogenes driven by eukaryotic promoters induce
eﬃcient humoral and cellular immune responses. Immu-
nization of Salmonella carrying a LLO-encoding expression
plasmid elicited protective immunity against a lethal dose
of L. monocytogenes challenge. As Salmonella is reported
to induce apoptosis when it enters macrophages, bystander
DC may capture the DNA vaccine plasmid through the
phagocytosis of Salmonella-infected apoptotic cells [54]. In
addition to oral Salmonella DNA vaccine administration,
the nasal route of administration has also been examined.
Darji et al. [55] compared the oral and nasal administration
of Salmonella harboring a eukaryotic expression plasmid
encoding β-gal. They showed that both routes could induce
systemic T-cell responses but nasal administration was
clearly inferior to oral administration. This may be due to
the lower number of bacteria that could be applied nasally.
Several investigators have improved the Salmonella car-
rier by introducing genes conferring invasiveness. Intro-
duction of the LLO gene of L. monocytogenes into the S.
Typhimurium aroA strain resulted in enhanced plasmid
delivery [56].
5.2.3. Listeria as a Carrier of DNA Vaccines. The ability of L.
monocytogenes to enter the host cytoplasm after phagocytosis
and deliver plasmid DNA directly into the cytoplasm makes
it an attractive DNA delivery platform for inducing cellular
immune responses.
Hense et al. [57]e v a l u a t e dListeria as a vehicle for gene
transfer using a variety of cell lines. They observed gene
transfer into host cells after treating cells infected with
plasmid-carrying Listeria with tetracycline, a bacteriostatic
antibiotic. They speculated that the metabolic block by tetra-
cycline treatment makes these bacteria susceptible to cellular
defense mechanisms and induces release of plasmid into the
host cell cytoplasm. They reported that bacterial properties
required for the delivery of eukaryotic expression plasmids
were strictly dependent on the ability of the bacteria to both
invade eukaryotic cells and egress from the vacuole into
the cytoplasm of the infected host cells. Dietrich et al. [58]
reported on the DNA vaccination system of an attenuated
self-destructing L. monocytogenes strain by demonstrating
the feasibility of the system in the cell culture system using a
deletion mutant of L. monocytogenes Δ2 that lacks the entire
lecithinase operon including the virulence-associated genes
actA, mpl,a n dplcB [59]. This strain can infect macrophages
and replicate in the cytoplasm but cannot spread to adjacent6 Journal of Biomedicine and Biotechnology
cells. This attenuated mutant was introduced with a plasmid
containing a gene for the lysis protein PLY118 of the listerial
bacteriophage A118. PLY118 expression was controlled by
the actA promoter, which is active when L. monocytogenes
is in the host cell cytoplasm. Thus, this L. monocytogenes
mutant escapes from the phagosome and then lyses when
the PLY118 gene is expressed in the cytoplasm. Autolysis
of the L. monocytogenes mutant apparently releases the
plasmid DNA into the host cell cytoplasm, allowing the
expression of the transgene in the host cells. We applied
this system for DNA vaccines against M. tuberculosis by
constructing self-destructing attenuated L. monocytogenes
Δ2 strains carrying eukaryotic expression plasmids for the
mycobacterial antigen 85 complex (Ag85A and Ag85B) and
MPT51 [60]. Intravenous immunization of BALB/c mice
by these Listeria-carrying DNA vaccines elicited signiﬁcant
protective responses against virulent M. tuberculosis.
However, these plasmids are lost from the carrier Listeria
in vivo [61]. Pilgrim et al. [62] modiﬁed the Listeria system
in order to stabilize the plasmid in the L. monocytogenes
carrier strain. They constructed an L. monocytogenes strain
that has the chromosomal deletion region compassing the
trpSgene(encodingtryptophanyl-tRNAsynthetase)andalso
the actA gene. Since the trpS gene is essential for bacterial
viability, the trpS-deleted Listeria can maintain itself only
in the presence of plasmids carrying the trpS gene. They
constructed DNA vaccine plasmids containing the trpS gene
in addition to the listerial autolysis cassette consisting of the
lysis gene of phage A118 (ply118) under the control of the
actA promoter, which is activated only in the cytoplasm of
infected mammalian host cells. They reported no plasmid
loss for more than 50 generations of Listeria.T h i sn e w
Listeria-carrying DNA vaccine allows cell-to-cell spread,
which was much more eﬃcient in DNA delivery than the
nonspreading counterparts like the Δ2 listerial strain.
6.De ndriticC ellV ac cinatio n
DC are the most powerful APC that initiate the primary
immune response. They capture pathogens and apoptotic
cells at the portal of entry sites in the body and then they
migrate to regional lymphoid organs where they present
antigens to naive T cells [63]. DC have a distinct ability to
prime naive T cells. Therefore, DC-based vaccines have been
powerful for tumors and infectious diseases.
DC vaccines have been examined for eﬃcacy as vaccines
against infectious diseases as well as cancer. There are several
strategies for using DC as vaccines against intracellular
bacteria, including ex vivo pulses with bacteria or bacterial
antigens or the transfer of genes encoding antigens to DC.
McShane et al. [64] showed that for immunization with
DC pulsed with CD4+-o rC D 8 + T-cell epitope peptides in
the M. tuberculosis antigen 85A (Ag85A), copresentation of
both epitope peptides on the same DC was required for
p r o t e c t i o n .B a d o v i n a ce ta l .[ 65] showed that vaccination
with LLO 91–99 peptide-coated DC generated CD8+ T
cells with the phenotype and function of memory cells in
a short time (4–6 days after immunization) and that the
early memory CD8+ T cells underwent vigorous secondary
expansion in response to a variety of booster immunizations
leading to elevated numbers of eﬀector and memory T cells
and enhanced protective immunity against Listeria challenge
infection.
Retroviral transduction is advantageous for long-term
antigen presentation in vivo because the transgene integrates
into the chromosome leading to gene expression throughout
the life of the cell and its progeny. In our previous study
[66], we showed that DC vaccination retrovirally transduced
with a minimal CTL epitope derived from L. monocytogenes
successfully induced the speciﬁc CTL and protective immu-
nity against lethal listerial challenge. We also found that the
retrovirally transduced DC vaccine was more eﬀective than
a CTL epitope peptide-pulsed DC vaccine or a minigene
DNA vaccine for eliciting protective immunity. We also
evaluatedretrovirallytransducedDCvaccinationwiththeM.
tuberculosis-derived Ag85A gene [67]. The results indicated
that DC vaccination successfully induced speciﬁc cellular
immunity, including immune responses of CD4+ Tc e l l s
and CD8+ CTL, as well as speciﬁc antibody responses. In
the system, the de novo synthesized Ag85A proteins in the
Ag85A gene-transduced DC are processed via the MHC class
I pathway to induce speciﬁc CD8+ T cells. Speciﬁc CD4+ T-
cell responses to the proteins may also be evoked through
the uptake of the secreted proteins by APC or direct antigen
presentation by Ag85A gene-transduced DC.
These results showed that DC vaccination eﬃciently
induces CD8+ CTL, which have the capacity to protect
vaccinated animals from pathogenic bacteria. DC vaccina-
tion would not be feasible for preventing acute infectious
diseases because it is laborious and costly; however, DC
vaccination could be a promising strategy against serious
chronic infectious diseases.
7.Recombinant VirusVaccination
Recombinant viral vector systems for gene therapy have been
developedandtheireﬃcacyhasbeenexaminedingenedeliv-
ery to DC and in direct immunization. Adenoviral vectors
have been shown to deliver antigen genes to DC. For exam-
ple, Wang et al. [68] reported that single intranasal immu-
nization of BALB/c mice with Ag85A recombinant human
adenovirus (type 5; Ad5) induced Ag85A-speciﬁc CD8+
and CD4+ T-cell responses and also provided protection
against intranasal inhalation of M. tuberculosis.H o w e v e r ,
preexisting immunity against viral proteins expressed by
the vector prevents eﬀective immunization [69]. Therefore,
immunogenicity of the rare adenovirus serotype 35 (Ad35)
combined with Ad5 ﬁber knob (Ad35k5) were examined,
and Ad5 ﬁber knob was found to be important for the
immunogenicity in mice and Rhesus monkeys [70].
Retroviral vectors based on murine leukemia virus have
been employed to express antigens in vivo. Splenic DC
were found to contain injected proviral DNA and were
able to eﬃciently present antigens to T cells [71], but
the retroviral vectors only infect dividing cells and do not
infect nondividing cells including DC. Therefore, antigen
expression and succeeding immune responses would be
limiting.Journal of Biomedicine and Biotechnology 7
Lentiviral vectors have been shown to eﬃciently trans-
duce a variety of nondividing cells [72, 73]. In addi-
tion, lentiviral vectors pseudotyped with minimal ﬁlovirus
e n v e l o p e sh a v eb e e nr e p o r t e dt oi n c r e a s eg e n et r a n s f e r
in murine lungs [74]. Third-generation self-inactivating
lentiviral vectors have been excellent viral vectors because
of their advanced safety proﬁle and the presumed absence
of preexisting antivector immunity, allowing in vivo admin-
straion.
We showed that third-generation lentivirus vectors,
which express the M. tuberculosis MPT51 antigen, eﬃciently
induced cell-mediated immunity against pulmonary tuber-
culosis with intratracheal instillation [75]. We also showed
that a single intratracheal MPT51 lentivirus administration
was eﬀective for inducing antigen-speciﬁc CD8+ T-cell
responses in the lung. Esslinger et al. [76] showed that
lentiviral vector injection into the footpad of mice was
capable of transducing regional DC which appeared in the
draining lymph nodes and in the spleen. They showed that
in vivo administration of lentivector was superior to the
transfer of transduced DC or peptide/adjuvant vaccination
in terms of both amplitude and longevity of the resul-
tant CTL response. These results conﬁrm the eﬀectiveness
of the lentiviral vector system for mucosal T cell-based
vaccination.
8. Improvement in Immunization Regimen:
Prime-Boost Immunization
Evaluation of vaccination has indicated that the repeated
injection of the same vaccine has a limitation in terms of
its overall immunological eﬀects. Especially, DNA immu-
nization has been reported to induce considerably strong
immunological responses in the rodents, but not in the
primates including human [77].
Instead of the repeated injection of the same vaccine,
the heterologous prime-boost regimen including DNA vac-
cination, which is primed with naked DNA vaccination and
boostedwithrecombinantviralvectorssuchasvacciniavirus
and adenovirus, has been shown to evoke superior levels
of immunity to DNA vaccine or recombinant virus alone
[78]. The relatively low-level but persistent expression of
immunogenic proteins in vivo by naked DNA vaccines has
been suggested to be important for priming immunological
responses and inducing enhanced cellular immunity [78].
Interestingly, Eo et al. [79] reported that mucosal immuno-
l o g i c a lr e s p o n s e sw e r eo p t i m a lw h e na n i m a l sw e r ep r i m e d
with the recombinant vaccinia virus vector and boosted with
a naked DNA vaccine, which is an opposite approach com-
pared to the regimen for systemic immunological responses.
Strong immunization by recombinant virus vaccines may
be necessary to give enough priming eﬀects in the mucous
membrane.
A variety of prime-boost regimens have been examined
for M. tuberculosis infection [80]. Many investigators exam-
ined the regimens in which priming with DNA vaccines
and boosting with other immunization strategies. Tanghe et
al. [81] immunized C57BL/6 mice ﬁrst with Ag85A DNA
vaccine and then with recombinant Ag85A proteins and
showed that this regimen induced stronger speciﬁc IFN-
γ responses and better protective immunity against M.
tuberculosis i. v. challenge compared to Ag85A DNA vaccine
alone. Similarly, ESAT6 protein boosting immunization
increased immune responses by ESAT6 DNA vaccines [82].
McShane et al. [83] showed that priming immunization
with ESAT6 and MPT63 DNA vaccines and boosting with
modiﬁed vaccinia virus Ankara (MVA) harboring Ag85A
gene (MVA85A) induced protective immunity against M.
tuberculosis infection compared to BCG immunization in
mice. Feng et al. [84] showed that priming with Ag85B
DNA vaccine and boosting with BCG vaccine strengthened
protective immunity against M. tuberculosis induced by BCG
vaccine alone in mice. Skinner et al. [85] also reported that
priming with ESAT6 and Ag85A DNA vaccines and boosting
with BCG vaccine enhanced speciﬁc IFN-γ production from
immunesplenocytescomparedwiththatbytheDNAvaccine
or BCG vaccine alone in mice. Furthermore, Romano et
al. [86] showed that immunization of BALB/c mice with
Ag85A DNA vaccine ﬁrst and boosting with BCG vaccine
inducedstrongerprotectiveimmunityagainstM.tuberculosis
challenge than that by Ag85A DNA vaccine alone. These
results demonstrated that DNA vaccine priming and BCG
vaccine boosting enhanced immune responses induced by
BCG vaccine alone.
The regimens in which BCG vaccine was used as a
priming vaccine also have been tried. As the BCG vaccine
has been injected to people all over the world, this regimen
seems to be reasonable. Priming with BCG vaccine and
intranasal boosting with MVA85A in mice enhanced Ag85A-
speciﬁc CD4+ and CD8+ T-cell responses and strengthened
protectiveimmunityagainstaerosolM.tuberculosischallenge
infectioninmice[87].Thisregimenwasreportedinhumans.
McShaneetal.[88]reportedthatinvolunteerswhohadbeen
vaccinated 0.5–38 years previously with BCG, vaccination
with MVA85A induced substantially higher levels of antigen-
speciﬁc IFN-γ-secreting T cells and that at 24 weeks after
vaccination, these levels were 5–30 times greater than in vac-
cinees administered a single BCG vaccination. Santosuosso
et al. [89] reported that intranasal immunization of mice
with recombinant Ag85A-expressing adenovirus after sub-
cutaneous BCG immunization augmented Ag85A-speciﬁc
CD4+ and CD8+ T-cell responses in the lung and protective
immunity against intratracheal M. tuberculosis infection.
WHO have showed a list of TB vaccine candidates (TB
vaccine pipeline: http://www.stoptb.org/retooling/). These
TB vaccine strategies are based on the prime-boost regimens
and the vaccine candidates are categorized into three vaccine
groups, namely, (1) priming vaccines, (2) boosting vaccines,
and (3) therapeutic vaccines after M. tuberculosis infection.
Reports on the prime-boost regimens by these TB vaccine
candidateshavebeenpublishing.Tchilianetal.[90]r eported
that priming with ΔureChly+ BCG and boosting with
MVA85A induced protective immunity against M. tubercu-
losis infection in mice. The protective eﬀects were much
higher in ΔureChly+ BCG vaccination than that in parental
BCG vaccination. MVA85A boost immunization enhanced
Ag85A-speciﬁc T-cell responses, but did not aﬀect bacterial
numbers in the lung after M. tuberculosis aerosol infection.8 Journal of Biomedicine and Biotechnology
9. Conclusions
A variety of immunization methods have been evaluated
and reported to induce speciﬁc CD8+ T cells against
intracellular bacterial infections. Modiﬁed BCG vaccines
have been examined to enhance CD8+ T-cell responses.
Naked DNA vaccination is a promising strategy to induce
CD8+ T cells. This method has a variety of advantages over
conventional attenuated bacterial vaccination, including a
relatively easy design and construction using recombinant
DNAtechnology,relativelylowcost,highstability,andsafety.
InadditiontothenakedDNAvaccinationstrategy,liveatten-
uated intracellular bacteria such as Shigella, Salmonella,a n d
Listeria have also been utilized as carriers of DNA vaccines
in animal models. Furthermore, a strong and immediate
induction of speciﬁc CD8+ T cells is expected with DC
vaccination. DC are the most potent antigen-presenting cells
in the body. Immunization of DC pulsed with antigenic
peptides or introduced with antigen genes by viral vectors
suchasretrovirusesisapowerfulstrategy.Recombinantvirus
vaccination, especially recombinant lentivirus vaccination,
has also been utilized to induce speciﬁc CD8+ T cells.
These strategies and combinations of diﬀerent strategies
(prime-boost immunization) have been examined for the
eﬃcient induction of intracellular bacteria-speciﬁc CD8+ T
cells.
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